咪喹莫特注射兔声带:一项初步的临床前研究
本研究为临床前研究,将100 µg无菌咪喹莫特(1 µg/µL)注射至6只新西兰白兔单侧声带,对侧注射100 µL生理盐水,评估喉水肿、组织病理学改变及血清干扰素α(IFNα)水平。结果显示注射后无呼吸道窘迫,声带外观及组织学无炎症或瘢痕,但血清IFNα在注射后第3天和第7天一过性升高(P < .0001和P = .0368),第14天恢复基线。结论认为声带咪喹莫特注射未导致明显并发症,但血清IFNα短暂升高。
要点
- 兔声带注射咪喹莫特未引起呼吸道窘迫、炎症病变或瘢痕。
- 组织学显示对照组和咪喹莫特组均无急性炎症过程或结构改变。
- 血清IFNα在注射后第3天和第7天一过性升高,第14天恢复基线。
核心结论
- 声带咪喹莫特注射在该临床前模型中未导致明显并发症,但血清IFNα浓度出现一过性升高。
研究设计与样本
- 临床前研究,6只新西兰白兔接受单侧声带注射100 µg无菌咪喹莫特(1 µg/µL),对侧注射100 µL生理盐水。
- 注射后第3、7、30天行直接喉镜检查,3只兔于第7天、3只于第30天取喉组织行组织学分析,并系列采血行免疫分析定量IFNα。
主要发现
- 任何时间点均未观察到呼吸道窘迫体征。
- 系列直接喉镜评估显示咪喹莫特组与对照组声带外观无临床差异。
- 注射后未发现炎症病变或瘢痕。
- 组织学显示对照组和咪喹莫特注射组均无急性炎症过程或结构改变迹象。
- 血清IFNα在咪喹莫特注射后第3天(P < .0001)和第7天(P = .0368)升高,第14天恢复基线。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective Given the recalcitrant nature of recurrent respiratory papillomatosis, targeted therapies to reduce disease burden are fundamental to improved patient care paradigms. We seek to demonstrate the safety of imiquimod injection into vocal fold mucosa by evaluating the degree of laryngeal edema, histopathologic changes to vocal fold structure, and serologic interferon α (IFNα) levels following injection. Study Design Preclinical. Setting Academic institution. Subjects and Methods Six New Zealand White rabbits underwent unilateral injection of 100 µg of sterile imiquimod (1 µg/µL), with 100 µL of normal saline injected into the contralateral vocal fold. Direct laryngoscopy was performed on days 3, 7, and 30 following injection. Larynges from 3 rabbits were harvested on postinjection day 7 for histologic analysis. The remaining 3 rabbit larynges were harvested on day 30. Serial serum samples were drawn for IFNα quantification via immunoassay. Results No signs of respiratory distress were observed at any point. Vocal fold appearance was not clinically divergent between imiquimod and control conditions via serial direct laryngoscopic evaluation. No inflammatory lesions or scarring were identified following injection. Histology showed no signs of acute inflammatory processes or changes in the control or imiquimod injection groups. Serum IFNα increased at days 3 and 7 following imiquimod injection ( P < .0001 and P = .0368, respectively), before returning to baseline by day 14. Conclusions Vocal fold imiquimod injection did not result in notable morbidity in this preclinical model. However, serum IFNα concentrations increased transiently. These data are critical to advance the therapeutic utility of this compound, particularly in the setting of recurrent respiratory papillomatosis.
引用
- Teng SE, Dion GR, Sin DN, et al. Imiquimod Injection to Rabbit Vocal Folds: A Preliminary, Preclinical Investigation. Otolaryngol Head Neck Surg. 2017. PMID: 28171734. doi:10.1177/0194599816689585
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。